CLAIMS:

1. Use of a first dose of a composition comprising human pluripotent stem cell-derived oligodendrocyte progenitor cells (OPCs) in the manufacture of a medicament for improving one or more neurological functions in a subject having a spinal cord injury (SCI), wherein the medicament optionally comprises two or more doses of the composition.
2. The use of claim 1, wherein the medicament further comprises a second dose of the composition.
3. The use of claim 1, wherein the medicament further comprises a third dose of the composition.
4. The use of any of claims 1-3, wherein the composition is adapted for injecting the composition into the spinal cord of the subject.
5. The use of any of claims 1-4, wherein the SCI is a subacute cervical SCI or a chronic cervical SCI.
6. The use of any of claims 1-4, wherein the SCI is a subacute thoracic SCI or a chronic thoracic SCI.
7. The use of any one of the preceding claims, wherein the first dose, second dose, and/or third dose of the composition comprises about 1×10^6 to about 3×10^7 OPC cells.
8. The use of any one of the preceding claims, wherein each of the first dose, second dose, and third dose of the composition is adapted for administration about 14 to about 90 days after the SCI.
9. The use of any one of the preceding claims, wherein each of the first dose, second dose, and third dose of the composition is adapted for administration between about 14 days after the SCI and the lifetime of the subject.
10. The use of any one of claims 4-9, wherein the injection is performed in a caudal half of an epicenter of the SCI.
11. The use of claim 10, wherein the injection is about 6 mm into the spinal cord of the subject or about 5 mm into the spinal cord of the subject.
12. Use of a dose of a composition comprising human pluripotent stem cell-derived oligodendrocyte progenitor cells (OPCs) in the manufacture for improving one or more

neurological functions in a subject having a spinal cord injury (SCI), wherein the composition is adapted for administration into the spinal cord of the subject.

13. The use of claim 12, wherein the dose of the composition comprises about 1 x 10^6 to about 3x10^7 OPC cells.
14. The use of any one of claims 12-13, wherein the composition is adapted for administration about 7 to about 14 days after the SCI.
15. The use of any one of claims 12-14, wherein the administration is performed in a caudal half of an epicenter of the SCI.
16. The use of any one of claims 12-15, wherein the administration is about 6 mm into the spinal cord of the subject or about 5 mm into the spinal cord of the subject.
17. The use of any one of claims 12-16 wherein the SCI is a subacute thoracic SCI or a chronic thoracic SCI.
18. The use of any one of claims 12-16 wherein the SCI is a subacute cervical SCI or a chronic cervical SCI.
19. The use of any one of the above claims, wherein improving one or more neurological functions comprises an improvement in ISNCSCI exam upper extremity motor score (UEMS).
20. The use of claim 19, where in the improvement in UEMS occurs within about 6 months, about 12 months, about 18 months, about 24 months or more after injection.
21. The use of claim 19 or 20, wherein the improvement is an increase in UEMS of at least 10%, compared to baseline.
22. The use of any one of the above claims, wherein improving one or more neurological functions comprises an improvement in lower extremity motor scores (LEMS).
23. The use of claim 22, where in the improvement in LEMS occurs within about 6 months, about 12 months, about 18 months, about 24 months or more after injection.
24. The use of claim 19 or 20, wherein the improvement is at least one motor level improvement.
25. The use of any one of claims 19-24, wherein the improvement is on one side of the subject’s body.
26. The use of any one of claims 19-24, wherein the improvement is on both sides of the subject’s body.

27. The use of any one of the preceding claims, wherein the dose of the composition is adapted for administration about 14 to about 90 days after the SCI.
28. The use of any one of the preceding claims, wherein the dose of the composition is adapted for administration between about 14 days after the SCI and the lifetime of the subject.